GANCICLOVIR


Trade Names	CYTOVENE GANCICLOVIR VITRASERT ZIRGAN
Synonyms	BW 759U BW-759U Cymevene Cytovene Ganciclovir Gancyclovir Ganzyk-rtu NSC-759656 RS-21592 Valganciclovir hydrochloride impurity a Virgan Vitrasert Zirgan
Status
Molecule Category	Free-form
ATC	J05AB06 S01AD09
UNII	P9G3CKZ4P5
EPA CompTox	DTXSID8041032


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	IRSCQMHQWWYFCW-UHFFFAOYSA-N
Smiles	Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
InChI	InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C9H13N5O4
Molecular Weight	255.23
AlogP	-1.56
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	5.0
Polar Surface Area	139.54
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	18.0

Pharmacology

Mechanism of Action	Action	Reference
Human herpesvirus 1 DNA polymerase inhibitor	INHIBITOR	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Transferase	-	-	15849	-	17
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	-	11

Related Entries

Cross References

Resources	Reference
ChEBI	465284
ChEMBL	CHEMBL182
DrugBank	DB01004
DrugCentral	1277
FDA SRS	P9G3CKZ4P5
Human Metabolome Database	HMDB0015139
PDB	GA2
PharmGKB	PA449733
PubChem	135398740
SureChEMBL	SCHEMBL3033
ZINC	ZINC000000001505

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).